Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function. Reported prevalence of this geriatric syndrome, differs depending on the definition, the population and the method used to identify sarcopenia. The causes of sarcopenia are multifactorial, and can include genetic influence, immobility or disuse, endocrine factors, inflammation and nutritional deficiencies. These disorders involve an imbalance between anabolic and catabolic pathways that rules muscle mass. Many drugs taken regularly for common conditions may interact with some mechanisms that can alter the balance between protein synthesis and degradation. This may lead to a harmful or a beneficial effect on muscle mass and strength. Widely prescribed drugs could play an important role during the time of onset and development of sarcopenia. In this paper, we reviewed the current understanding of how can drugs contribute positively or negatively on sarcopenia and muscle wasting. We decided to focus this review on oral common drugs, which are usually prescribed in older adults, leaving aside other drugs as hormone therapy.

Keywords:
Sarcopenia, Angiotensin-converting enzyme inhibitors, Statins, Antidiabetic drugs, Vitamin D, Muscle wasting
1.
Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, de Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12:249-256.
2.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People: Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010;39:412-423.
3.
Clark BC, Manini TM: Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci 2008;63:829-834.
4.
Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C, Stout JR, Studenski SA, Vellas B, Woo J, Zamboni M, Cederholm T: Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the international sarcopenia initiative (EWGSOP and IWGS). Age Ageing 2014;43:748-759.
5.
Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-1019.
6.
Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M: Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013;280:4294-4314.
7.
Morley JE, Anker SD, von Haehling S: Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014;5:253-259.
8.
Ali S, Garcia JM: Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology 2014;60:294-305.
9.
von Haehling S, Steinbeck L, Doehner W, Springer J, Anker SD: Musclewasting in heart failure: an overview. Int J BiochemCell Biol 2013;45:2257-2265.
10.
Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS: The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997;52:M201-M208.
11.
Rolland Y, Onder G, Morley JE, Gillette-Guyonet S, Abellan van Kan G, Vellas B: Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med 2011;27:423-447.
12.
Onder G, Vedova CD, Pahor M: Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 2006;12:2057-2064.
13.
Sumukadas D, Struthers AD, McMurdo ME: Sarcopenia - a potential target for angiotensin-converting enzyme inhibition? Gerontology 2006;52:237-242.
14.
Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M: Relation between use of angiotensinconverting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002;359:926-930.
15.
Sumukadas D, Witham MD, Struthers AD, et al: ACE inhibitors as a therapy for sarcopenia - evidence and possible mechanisms. J Nutr Health Aging 2008;12:480-485.
16.
Witham MD, Sumukadas D, McMurdo ME: ACE inhibitors for sarcopenia - as good as exercise training? Age Ageing 2008;37:363-365.
17.
Sumukadas D, Witham MD, Struthers AD, et al: Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007;177:867-874.
18.
Ogawa S, Mori T, Nako K, et al: Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47:699-705.
19.
Takagi H, Mizuno Y, Yamamoto H, Goto SN, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group: Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 2013;36:368-373.
20.
Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD: Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011;3:82ra37.
21.
Lin CH, Yang H, Xue QL, Chuang YF, Roy CN, Abadir P, Walston JD: Losartan improves measures of activity, inflammation, and oxidative stress in older mice. Exp Gerontol 2014;58:174-178.
22.
ClinicalTrials.gov: A Study of Muscle Strength Maintenance in Older Adults. Bethesda, National Library of Medicine (US), 2013. https://clinicaltrials.gov/ct2/show/NCT01989793 (cited June 21, 2015).
23.
Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2011. Atlanta, Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
24.
Sinclair A, Morley JE, Rodriguez-Mañas L, Paolisso G, Bayer T, Zeyfang A, et al: Diabetes mellitus in older people: position statement on behalf of the international association of gerontology and geriatrics (IAGG), the European diabetes working party for older people (EDWPOP), and the international task force of experts in diabetes. J Am Med Dir Assoc 2012;13:497-502.
25.
Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al: Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 2013;14:585-592.
26.
Kim KS, Park KS, Kim MJ, Kim SK, Cho YW, Park SW: Type 2 diabetes is associated with low muscle mass in older adults. Geriatr Gerontol Int 2014;14(suppl 1):115-121.
27.
Cetrone M, Mele A, Tricarico D: Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr Diabetes Rev 2014;10:231-237.
28.
Perez A, Jacks R, Arora V, et al: Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 2010;12:973-982.
29.
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-2081.
30.
Dungan CM, Li Z, Wright DC, Williamson DL: Hyperactive mTORC1 signaling is unaffected by metformin treatment in aged skeletal muscle. Muscle Nerve 2016;53:107-117.
31.
ClinicalTrials.gov: Metformin and Muscle in Insulin-Resistant Older Veterans. Bethesda, National Library of Medicine (US), 2013. https://clinicaltrials.gov/ct2/show/NCT01804049 (cited June 21, 2015).
32.
Miyazaki Y, Mahankali A, Matsuda M, et al: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
33.
Wang X, Hu Z, Hu J, Du J, Mitch WE: Insulin resistance accelerates muscle protein degradation: activation of the ubiquitinproteasome pathway by defects in muscle cell signaling. Endocrinology 2006;147:4160-4168.
34.
Asp ML, Tian M, Wendel AA, Belury MA: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 2010;126:756-763.
35.
Tricarico D, Camerino DC: ATP-sensitive K+ channels of skeletal muscle fibers from young adult and aged rats: possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties. Mol Pharmacol 1994;46:754-761.
36.
Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY: Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-506.
37.
Wajchenberg BL: Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
38.
Mele A, Buttiglione M, Cannone G, Vitiello F, Camerino DC, Tricarico D: Opening/blocking actions of pyruvate kinase antibodies on neuronal and muscular KATP channels. Pharmacol Res 2012;66:401-408.
39.
Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D: Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect 2014;2:e00028.
40.
Malaisse WJ: Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-414.
41.
Doyle ME, Egan JM: Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-593.
42.
Buteau J: GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008;34(suppl 2):73-77.
43.
Nyström T: The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008;40:593-606.
44.
Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z: Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012;61:888-896.
45.
Bruckert E, Hayem G, Dejager S, Yau C, Begaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414.
46.
Wei M, Ito MK, Cohen JD, Brinton EA, Jacobson TA: Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013;7:472-483.
47.
Jones JD, Kirsch HL, Wortmann RL, Pillinger MH: The causes of drug-induced muscle toxicity. Curr Opin Rheumatol 2014;26:697-703.
48.
Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-2237.
49.
Itagaki M, Takaguri A, Kano S, et al: Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 2009;109:94-101.
50.
Smith R, Solberg R, Jacobsen LL, et al: Simvastatin inhibits glucose metabolism and legumain activity in human myotubes. PLoS One 2014;9:e85721.
51.
Phillips PS, Haas RH, Bannykh S, et al: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
52.
Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206-1210.
53.
Scott D, Blizzard L, Fell J, Jones G: Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009;102:625-633.
54.
Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC: Vitamin D: current status and perspectives. Clin Chem Lab Med 2009;47:120-127.
55.
Ensrud KE, Blackwell TL, Cauley JA, et al; Osteoporotic Fractures in Men Study Group: Circulating 25-hydroxyvitamin D levels and frailty in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 2011;59:101-106.
56.
Morley JE: Should all long-term care residents receive vitamin D? J Am Med Dir Assoc 2007;8:69-70.
57.
Tajar A, Lee DM, Pye SR, et al: The association of frailty with serum 25-hydroxyvitamin D and parathyroid hormone levels in older European men. Age Ageing 2012;42:352-359.
58.
Braddy KK, Imam SN, Palla KR, et al: Vitamin D deficiency/insufficiency practice patterns in a veterans health administration long-term care population: a retrospective analysis. J Am Med Dir Assoc 2009;10:653-657.
59.
Islam T, Peiris P, Copeland RJ, et al: Vitamin D: lessons from the veterans population. J Am Med Dir Assoc 2011;12:257-262.
60.
Montero-Odasso M, Duque G: Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005;26:203-219.
61.
Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266-281.
62.
Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al: Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004;80:752-758.
63.
Visser M, Deeg DJ, Lips P: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab 2003;88:5766-5772.
64.
Yoshikawa S, Nakamura T, Tanabe H, Imamura T: Osteomalacic myopathy. Endocrinol Jpn 1979;26(suppl):65-72.
65.
Palmucci L, Bertolotto A, Doriguzzi C, Mongini T, Coda R: Osteomalacic myopathy in a case of diffuse nodular lipomatosis of the small bowel. Acta Neurol Belg 1982;82:65-71.
66.
Domingues-Faria C, Chanet A, Salles J, Berry A, Giraudet C, Patrac V, Denis P, Bouton K, Goncalves-Mendes N, Vasson MP, Boirie Y, Walrand S: Vitamin D deficiency down-regulates Notch pathway contributing to skeletal muscle atrophy in old Wistar rats. Nutr Metab (Lond) 2014;11:47.
67.
Wicherts IS, van Schoor NM, Boeke AJ, et al: Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007;92:2058-2065.
68.
Houston DK, Tooze JA, Neiberg RH, et al: 25-Hydroxyvitamin D status and change in physical performance and strength in older adults: the health, aging, and body composition study. Am J Epidemiol 2012;176:1025-1034.
69.
Houston DK, Cesari M, Ferrucci L, et al: Association between vitamin D status and physical performance: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2007;62:440-446.
70.
Flicker L, Mead K, MacInnis RJ, et al: Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003;51:1533-1538.
71.
Faulkner KA, Cauley JA, Zmuda JM, et al: Higher 1,25-dihydroxyvitamin D3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int 2006;17:1318-1328.
72.
Snijder MB, van Schoor NM, Pluijm SM, et al: Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J Clin Endocrinol Metab 2006;91:2980-2985.
73.
Rizzoli R, Stevenson JC, Bauer JM, van Loon LJ, Walrand S, Kanis JA, Cooper C, Brandi ML, Diez-Perez A, Reginster JY; ESCEO Task Force: The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Maturitas 2014;79:122-132.
74.
Rousseau AF, Foidart-Desalle M, Ledoux D, Remy C, Croisier JL, Damas P, Cavalier E: Effects of cholecalciferol supplementation and optimized calcium intakes on vitamin D status, muscle strength and bone health: a one-year pilot randomized controlled trial in adults with severe burns. Burns 2015;41:317-325.
75.
Muir SW, Montero-Odasso M: Effect of vitamin D supplementation on musclestrength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2011;59:2291-2300.
76.
Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H, et al: A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab 2013;98:E1927-E1935.
77.
Stockton KA, Mengersen K, Paratz JD, et al. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int 2011;22:859-871.
78.
Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 2005;20:187-192.
79.
Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K, Muscaritoli M, Ponikowski P, Posthauer ME, Rossi Fanelli F, Schambelan M, Schols AM, Schuster MW, Anker SD; Society for Sarcopenia, Cachexia, and Wasting Disease: Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010;11:391-396.
80.
Aranda R, Domenech E, Rus AD, Real JT, Sastre J, Vina J, et al: Age-related increase xanthine oxidase activity in human plasma and rat tissues. Free Radic Res 2007;41:1195-1200.
81.
Lambertucci RH, Levada-Pires AC, Rossoni LV, Curi R, Pithon-Curi TC: Effects of aerobic exercise training on antioxidant enzyme activities and mRNA levels in soleus muscle from young and aged rats. Mech Ageing Dev 2007;128:267-275.
82.
Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, et al: Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 2012;131:2187-2196.
83.
Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W: The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-inducedcardiomyopathy. Int J Cardiol 2013;168:3527-3531.
84.
Kondo H, Nakagaki I, Sasaki S, Hori S, Itokawa Y: Mechanism of oxidative stress in skeletal muscle atrophied by immobilization. Am J Physiol 1993;265(6 pt 1):E839-E844.
85.
Derbre F, Ferrando B, Gomez-Cabrera MC, Sanchis-Gomar F, Martinez-Bello VE, Olaso-Gonzalez G, et al: Inhibition of xanthine oxidase by allopurinol preventsskeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases. PLoS One 2012;7:e46668.
86.
Beveridge LA, Ramage L, McMurdo ME, George J, Witham MD: Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age Ageing 2013;42:400-404.
87.
Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, et al: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004;64:6725-6731.
88.
Ametller E, Busquets S, Fuster G, et al: Formoterol may activate rat muscle regeneration during cancer cachexia. Insciences J 2011;1:1-17.
89.
Argilés JM, López-Soriano FJ, Busquets S: Novel approaches to the treatment of cachexia. Drug Discov Today 2008;13:73-78.
90.
Toledo M, Springer J, Busquets S, Tschirner A, López-Soriano FJ, Anker SD, Argilés JM: Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014;5:315-320.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.